Virax Biolabs Group Limited (VRAX) CEO James Foster issued a shareholder letter detailing the company's progress in immunology research, particularly in post viral syndromes and chronic inflammation. The company has developed a SARS-Cov-2 version of its ViraxImmune T-Cell Kit and is collaborating with a UK research institute. Virax is also enhancing its IVD platform with FluoroSpot technology for better immune response analysis. Financially, Virax is in a strong position with $5.6 million in cash and no debt after a warrant exercise in October 2023. The stock is currently trading at 57% of cash value. The company anticipates significant advancements in its FluoroSpot assays and expansion of distribution channels in the next 12 months.